Mobia Medical (MOBI) Q2 2026 Earnings Call Transcript
Mobia Medical (MOBI) reported Q2 2026 revenue of $13.5M, up 102% YoY, driven by Vivistim system adoption. Full-year guidance set at $54M-$56M. Net loss was $21M, with cash reserves of $177.1M post-IPO. Management plans to expand active territories and target 1,500 U.S. stroke centers.
How this was made
The 30-second read
Why it matters
Traders can update models around FY2026 revenue ($54M-$56M), territory growth (35.5 active territories), and unit sales (367 Vivistim units), while monitoring reimbursement-rule finalization risk for 2027.
Market read
Fresh Q2 operating metrics and explicit FY2026 revenue guidance are the main tradable inputs, with reimbursement final-rule timing as the key uncertainty.
What to watch
CMS’s 2027 New Tech APC 1580 is only a proposal until the November final rule, which could change reimbursement economics and affect the pace of territory expansion.
Background
Mobia Medical is scaling commercialization of its FDA-approved Vivistim therapy for chronic ischemic stroke, using an active territory model and hospital program launches.
Ticker impact
Mobia Medical reported Q2 2026 revenue of $13.5M (+102% YoY) and guided full-year 2026 revenue to $54M-$56M.
Moderately positive bias, with upside contingent on continued territory adds and reimbursement stability.
Revenue growth, active territory expansion, and explicit FY guidance are concrete catalysts, but the call also highlights reimbursement rule uncertainty (CMS final rule timing) and a large net loss.
Market effects
Reinforces investor focus on reimbursement durability and territory scaling for neurostimulation/rehab medtech commercialization models.
Primarily US-focused given CMS APC 1580 and targeted stroke centers.
Limited direct global read-through because the reimbursement framework and center targeting are US-specific.
Counterpoint
Despite strong revenue growth, the company’s net loss widened to $21.0M and commercialization costs rose sharply, so the guidance may still be fragile if reimbursement or hospital adoption slows.
Key entities
- issuerMobia Medical, Inc.
Reported Q2 2026 results and provided full-year 2026 revenue guidance on the earnings call.
- productVivistim
Paired VNS therapy system whose adoption and utilization drove Q2 revenue growth.
- regulatoryCMS New Tech APC 1580
2027 reimbursement designation is currently a proposal pending a final rule in November.
